A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Clinical trial NCT05418673 · TERMINATED

Trial details

NCT number: NCT05418673
Sponsor: Biogen
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2022-08-26
Primary completion: 2023-07-27
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.